Avandia Recall Imminent? New Study Confirms Drug's Heart Attack & Stroke Risks
Bolstered in their pursuits by the results of a second study, the scientists that first raised the alarm about Avandia's dangers are calling for it to be pulled from the market. They might get their wish as outside advisers to the FDA will consider the issue in mid-july.
The second study found that one out of every 52 patients taking Avandia was harmed by the drug. Those results may provide the impetus the FDA needs to take action, according to the new study by the Cleveland Clinic.
Avandia underwent a similar analysis in 2007 but was kept on the market. The recent findings coupled with the old evidence could lead to a different result this time, according to a pair of articles recently published in Business Week.
Avandia has been linked to heart attacks and other cardiovascular complications. According to an FDA safety reviewer, almost 50,000 elderly Americans have died, suffered strokes, or developed heart failure after taking Avandia instead of a rival medicine.
Avandia lawsuits coupled with it being pulled from the market could cost GlaxoSmithKline dearly. Avandia generated more than $1.1 billion in revenue last year alone and the company has already agreed to pay out $60 million in an earlier round of lawsuits.
Those injured by Avandia should consider discussing their case with a pharmaceutical attorney. The attorneys at Bahe Cook Cantley & Jones are actively litigating many cases involving dangerous drugs. To consult with attorney Shawn Cantley about Avandia: [profile, Shawn's Mail]
For the full text of the Business Week articles: here and here.
